Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia
Oncology Research · 2025
DOI: 10.32604/or.2025.075217 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Research, 2025. Verfasst von Masanobu Tsubaki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacotherapy, Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 8-53 Hamanocho, Takamatsu, 760-8542, …. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors, Fusion Proteins, bcr-abl. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Pharmacotherapy, Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 8-53 Hamanocho, Takamatsu, 760-8542, Kagawa, Japan.
Zitieren
APA
Tsubaki, M., Matsuo, T., & Komori, R. (2025). Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. Oncology Research. https://doi.org/10.32604/or.2025.075217
Vancouver
Tsubaki M, Matsuo T, Komori R. Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. Oncology Research. 2025. doi:10.32604/or.2025.075217
BibTeX
@article{Tsubaki2025,
author = {Tsubaki, Masanobu and Matsuo, Taira and Komori, Rie},
title = {Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia},
journal = {Oncology Research},
year = {2025},
doi = {10.32604/or.2025.075217}
}
EUVIMED